Cancer Genetics and Epigenetics, 2025, Vol.13, No.3, 126-135 http://medscipublisher.com/index.php/cge 135 Wang J., Su J., Yang W., Chen W., Wang Z., Liu W., Huang M., and Xu Y., 2025, Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer, Cancer Drug Resistance, 8: 22. https://doi.org/10.20517/cdr.2025.35 Wang X., Wang Z., Su X., Liu Y., Sun L., Zhou W., and Yang Y., 2022, Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions, Pakistan Journal of Pharmaceutical Sciences, 35(1 (Special)): 381-386. Wang X., You J., Zhang S., Liu W., Zhang H., and Chen D., 2021, The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer, Medicine, 100(30): e26714. https://doi.org/10.1097/MD.0000000000026714 Waterkamp D., Giantonio B., Hurwitz H., Kabbinavar F., Guan Z., Mitchell L., Tebbutt N., and Tabernero J., 2013, Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials, The Oncologist, 18(9): 1004-1012. https://doi.org/10.1634/theoncologist.2013-0107 Wichelmann T.A., Abdulmujeeb S., and Ehrenpreis E.D., 2021, S209 a review of adverse drug reactions for bevacizumab-awwb and Bevacizumab-bvzr in the treatment of metastatic colorectal cancer reported to the FDA adverse event reporting system database, The American Journal of Gastroenterology, 116: S93. https://doi.org/10.14309/01.ajg.0000773308.28844.89 Yeung Y., and Tebbutt N., 2012, Bevacizumab in colorectal cancer: current and future directions, Expert Review of Anticancer Therapy, 12: 1263-1273. https://doi.org/10.1586/era.12.104 Yoshida, H., Yamada T., Sonoda H., Watanabe T., Koda K., Yoshida Y., Hasegawa S., Otsuka T., Kosugi C., Hirata K., Matsuda A., Matsuoka H., Fukazawa A., Ohta R., Takahashi M., Kuramochi H., and Sakamoto K., 2022, Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study), International Journal of Clinical Oncology, 27: 1859-1866. https://doi.org/10.1007/s10147-022-02243-4 Yoshino T., Ishihara S., Kuboki Y., Kajiwara T., Takashima A., Terazawa T., Taniguchi H., Ozawa D., Makiyama A., Kotaka M., Sugimoto N., Kawakami H., Sunakawa Y., Ojima H., Morita S., Watanabe J., Kagawa Y., Masuishi T., Hara H., Nakajima T., Shirao K., Nakamura M., Takenaka N., and Oki E., 2023, Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial, British Journal of Cancer, 128(10): 1897-1905. https://doi.org/10.1038/s41416-023-02212-2 Zeng W., Liu B., Jiang J., Zheng J., Zhong Z., Huang S., Luo D.D., and Zheng B., 2025, The adverse reactions of bevacizumab in combination with the FOLFOX chemotherapy regimen in metastatic colorectal cancer, Expert Opinion on Drug Safety, 13: 1-11. https://doi.org/10.1080/14740338.2025.2490274 Zhang W., Liang P., Cui C., Li B., Yang W., Zhang J., Wu G., Sun Y., and Zhong X., 2025, Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer, Journal of Clinical Oncology, 43(4_suppl): 55. https://doi.org/10.1200/jco.2025.43.4_suppl.155 Zhou M., Xu L., Shen F., Qu C., Zheng Y., Cao J., and Zhang Y., 2015, Value of bevacizumab in treatment of colorectal cancer: a meta-analysis, World Journal of Gastroenterology, 21(16): 5072-80. https://doi.org/10.3748/wjg.v21.i16.5072 Zondor S., and Medina P., 2004, Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies, Annals of Pharmacotherapy, 38: 1258-1264. https://doi.org/10.1345/aph.1D470 Zhao Z.Y., Wu H.D., Sun H.M., and Zhao Y., 2024, Genetic mutation profiles of colorectal cancer and their prospects in diagnosis, Cancer Genetics and Epigenetics, 12(6): 317-328. https://doi.org/10.5376/cge.2024.12.0030 Zhang Y.R., Deng Y.H., Zhang M., Wang X., and Wang F., 2024, Mapping the tumor microenvironment in colon cancer with spatial transcriptomics, International Journal of Molecular Medical Science, 14(5): 293-304. https://doi.org/10.5376/ijmms.2024.14.0030
RkJQdWJsaXNoZXIy MjQ4ODYzNA==